© 2022 MJH Life Sciences and OncLive – Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive – Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Pegram discusses approaches to treatment sequencing in HER2-positive metastatic breast cancer, the influence of the DESTINY-Breast03 trial (NCT03529110) on the breast cancer treatment paradigm, and ongoing research in the field.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Seagen, we had the pleasure of speaking with Mark Pegram, MD, the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology and associate dean for Clinical Research Quality at Stanford University School of Medicine and associate director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). Pegram joined us to discuss treatment sequencing in metastatic HER2-positive breast cancer.
Many recent trials and approvals have paved the way for exciting treatment opportunities in breast cancer. For instance, in May 2022, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) as a second-line therapy for adult patients with unresectable or metastatic HER2-positive breast cancer, based on findings from the phase 3 DESTINY-Breast03 trial (NCT03529110). This trial showed that treatment with trastuzumab deruxtecan provided superior progression-free survival (PFS) and overall survival (OS) compared with ado-trastuzumab emtansine (T-DM1; Kadcyla).
In our exclusive interview, Pegram discussed approaches to treatment sequencing, the influence of the DESTINY-Breast03 trial (NCT03529110) on the breast cancer treatment paradigm, and ongoing research in the field.
Thank you for listening to this episode of OncLive On Air®, sponsored by Seagen. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.